The latest price target for Citius Oncology (NASDAQ:CTOR) was reported by Maxim Group on September 23, 2025. The analyst firm set a price target for $6.00 expecting CTOR to rise to within 12 months (a possible 693.13% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Citius Oncology (NASDAQ:CTOR) was provided by Maxim Group, and Citius Oncology upgraded their buy rating.

The last upgrade for Citius Oncology Inc happened on September 23, 2025 when Maxim Group raised their price target to $6. Maxim Group previously had a hold for Citius Oncology Inc.

The last downgrade for Citius Oncology Inc happened on May 23, 2025 when Maxim Group changed their price target from N/A to N/A for Citius Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Oncology was filed on September 23, 2025 so you should expect the next rating to be made available sometime around September 23, 2026.

While ratings are subjective and will change, the latest Citius Oncology (CTOR) rating was a upgraded with a price target of $0.00 to $6.00. The current price Citius Oncology (CTOR) is trading at is $0.76, which is within the analyst’s predicted range.